Alexander JH, Singh KP. Inhibition of factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovasc Drugs 2005; 5(5): 279–90 ArticlePubMedCAS Google Scholar
Tincani E, Crowther MA, Turrini F, et al. Prevention and treatment of venous thromboembolism in the elderly patient. Clin Interv Aging 2007; 2(2): 237–46 PubMedCAS Google Scholar
Nutescu EA, Shapiro NL, Feinstein H, et al. Tinzaparin: considerations for use in clinical practice. Ann Pharmacother 2003 Dec; 37(12): 1831–40 ArticlePubMedCAS Google Scholar
Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337(10): 663–9 ArticlePubMedCAS Google Scholar
Clark NP. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res 2008; 123 Suppl. 1: S58–61 ArticlePubMedCAS Google Scholar
Hull RD, Pineo GF, Brant RF, et al. Long-term lowmolecular-weight heparin versus usual care in proximalvein thrombosis patients with cancer. Am J Med 2006 Dec; 119(12): 1062–72 ArticlePubMedCAS Google Scholar
Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: lowmolecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006 May 2; 144(9): 673–84 PubMedCAS Google Scholar
U.S. Pharmacopeia. 2009 USP dictionary of USAN and international drug names. Rockville (MD): U.S. Pharmacopeia, 2009 Google Scholar
Nader HB, Walenga JM, Berkowitz SD, et al. Preclinical differentiation of low molecular weight heparins. Semin Thromb Hemost 1999; 25 Suppl. 3: 63–72 PubMed Google Scholar
Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999; 25 Suppl. 3: 5–16 PubMedCAS Google Scholar
Cheer SM, Dunn CJ, Foster R. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs 2004; 64(13): 1479–502 ArticlePubMedCAS Google Scholar
Friedel HA, Balfour JA. Tinzaparin: a review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 1994; 48(4): 638–60 ArticlePubMedCAS Google Scholar
Sweetman SC, editor. Martindale: the complete drug reference. 36th ed. London: Pharmaceutical Press, 2009 Google Scholar
Kuczka K, Baum K, Picard-Willems B, et al. Long-term administration of LMWH: pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients. Thrombosis Res 2009 Nov; 124(5): 625–30 ArticleCAS Google Scholar
Bara L, Planes A, Samama M-M. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999; 104: 230–40 ArticlePubMedCAS Google Scholar
Christidou FN, Frangia TK, Bamichas GI, et al. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis. Int J Clin Pharmacol Ther 2005 Jul; 43(7): 335–8 PubMedCAS Google Scholar
Sabry A, Taha M, Nada M, et al. Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens. Blood Coagul Fibrinolysis 2009 Jan; 20(1): 57–62 ArticlePubMed Google Scholar
Badawi L, Akeel N, Shaheen FAM, et al. Dose and lipid lowering effect of tinzaparin sodium: a single center experience. Saudi J Kidney Dis Transpl 2005 Apr–Jun; 16(2): 161–5 PubMed Google Scholar
Koutsikos D, Fourtounas C, Kapetanaki A, et al. A crossover study of a new low molecular weight heparin (Logiparin®) in hemodialysis. Int J Artif Organs 1996; 19(8): 467–71 PubMedCAS Google Scholar
Gouin-Thibault I, Pautas E, Depasse F, et al. Heparinreleasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dosages for up to 30 days. J Thromb Haemost 2003; 1: 2694–5 ArticlePubMedCAS Google Scholar
Elisaf MS, Germanos NP, Bairaktari HT, et al. Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Am J Nephrol 1997; 17: 153–7 ArticlePubMedCAS Google Scholar
Akiba T, Tachibana K, Ozawa K, et al. Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis. ASAIO J 1992; 38(3): M326–30 ArticlePubMedCAS Google Scholar
Fossler MJ, Barrett JS, Hainer JW, et al. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Am J Health Syst Pharm 2001 Sep 1; 58(17): 1614–21 PubMedCAS Google Scholar
Mätzsch T, Bergqvist D, Hedner U, et al. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57(1): 97–101 PubMed Google Scholar
Holst J, Lindblad B, Bergqvist D, et al. Protamine neutralization of intravenous and subcutaneous low-molecularweight heparin (tinzaparin, Logiparin™): an experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis 1994; 5(5): 795–803 ArticlePubMedCAS Google Scholar
Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol 2003 Jul; 43(7): 727–34 PubMedCAS Google Scholar
Depasse F, González de Suso MJ, Lagoutte I, et al. Comparative study of the pharmacokinetic profiles of two LMWHs — bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa) — administered subcutaneously to healthy male volunteers. Thromb Res 2003 Jan 25; 109(2–3): 109–17 ArticlePubMedCAS Google Scholar
Ellison J, Thomson AJ, Conkie JA, et al. Thromboprophylaxis following caesarean section: a comparison of the antithrombotic properties of three low molecular weight heparins — dalteparin, enoxaparin and tinzaparin. Thromb Haemost 2001 Dec; 86(6): 1374–8 PubMedCAS Google Scholar
Yoneda M, Brosnan JF, Norris LA, et al. The effect of LMWH (tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosis. Thromb Res 2006; 117(3): 283–90 ArticlePubMedCAS Google Scholar
Crowther MA, Berry LR, Monagle PT, et al. Mechanisms responsible for the failure of protamine to inactivate lowmolecular-weight heparin. Br J Haematol 2002; 116(1): 178–86 ArticlePubMedCAS Google Scholar
Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 1988; 50(6): 815–26 ArticlePubMedCAS Google Scholar
Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71(3): 300–4 PubMedCAS Google Scholar
Padilla A, Gray E, Pepper DS, et al. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992 Oct; 82: 406–13 ArticlePubMedCAS Google Scholar
Gerotziafas GT, Petropoulou AD, Verdy E, et al. Effect of the anti-factor Xa and anti-factor IIa activities of lowmolecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007 May; 5(5): 955–62 ArticlePubMedCAS Google Scholar
Leo Laboratories Limited. Innohep 10,000 IU/ml and Innohep syringe 10,000 IU/ml: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2010 Apr 12]
Leo Laboratories Limited. Innohep 20,000 IU/ml and Innohep syringe 20,000 IU/ml: summary of product characteristics [online]. Available from URL: http://emc.medcines.org.uk/ [Accessed 2010 Apr 12]
Weitz JI. Low-molecular-weight heparins [published erratum appears in N Engl J Med 1997 Nov 20; 337 (21): 1567]. N Engl J Med 1997 Sep 4; 337(10): 688–98 ArticlePubMedCAS Google Scholar
Planès A, Samama MM, Lensing AWA, et al. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81: 22–5 PubMed Google Scholar
Cambus J-P, Saivin S, Heilmann J-J, et al. The pharmacodynamics of tinzaparin in healthy volunteers. Br J Haematol 2002 Mar; 116(3): 649–52 ArticlePubMedCAS Google Scholar
Barrett JS, Gibiansky E, Hull RD, et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 2001 Oct; 39(10): 431–46 PubMedCAS Google Scholar
Johansen PB, Rasmussen SN, Østergaard PB. Pharmacokinetics of tinzaparin (Logiparin®) — a low molecular weight heparin — after single and repeated intravenous administration in rats. Thromb Res 1994 Aug 15; 75(4): 453–64 ArticlePubMedCAS Google Scholar
Mahé I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007 Apr; 97(4): 581–6 PubMed Google Scholar
Siguret V, Pautas E, Février M, et al. Elderly patients treated with tinzaparin (Innohep®) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000 Nov; 84(5): 800–4 PubMedCAS Google Scholar
Siguret V, Leizorovicz A, Pautas E, et al. No accumulation of peak anti-Xa activity of tinzaparin in elderly patients with moderate to severe renal impairment: a substudy of IRIS clinical trial [abstract no. 172]. Blood 2009; 114(22): 77 Google Scholar
Pautas E, Gouin I, Bellot O, et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25(10): 725–33 ArticlePubMedCAS Google Scholar
Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005 Dec; 94(6): 1164–71 PubMedCAS Google Scholar
Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavyweight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002 May; 87(5): 817–23 PubMedCAS Google Scholar
Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous lowmolecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992 Apr 9; 326(15): 975–82 ArticlePubMedCAS Google Scholar
Smith MP, Norris LA, Steer PJ, et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190(2): 495–501 ArticlePubMedCAS Google Scholar
Parent F, Deruelle P, Jaïs X, et al. Treatment of venous thromboembolism during pregnancy with a once-daily regimen of LMWH [abstract no. PP-MO-376]. J Thromb Haemost 2009 Jul; 7 Suppl. 2: 445 Article Google Scholar
Andersen AS, Berthelsen JG, Bergholt T. Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin. Acta Obstet Gynecol Scand 2010; 89(1): 15–21 ArticlePubMedCAS Google Scholar
Ní Áinle F, Wong A, Appleby N, et al. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis 2008 Oct; 19(7): 689–92 ArticlePubMed Google Scholar
Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993 Nov 4; 329(19): 1370–6 ArticlePubMedCAS Google Scholar
Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991 Feb; 62(1): 33–8 ArticlePubMedCAS Google Scholar
Leizorovicz A, Picolet H, Peyrieux JC, et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 1991; 78(4): 412–6 Article Google Scholar
Bergqvist D, Flordal PA, Friberg B, et al. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery: a double-blind multicenter trial. Vasa 1996; 25(2): 156–60 PubMedCAS Google Scholar
Jørgensen PS, Warming T, Hansen K, et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. Thromb Res 2002 Mar 15; 105(6): 477–80 ArticlePubMed Google Scholar
Lassen MR, Borris LC, Jensen HP, et al. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. Clin Appl Thromb Hemost 2000 Jan; 6(1): 53–7 ArticlePubMedCAS Google Scholar
Lausen I, Jensen R, Jorgensen LN, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 1998; 164(9): 657–63 ArticlePubMedCAS Google Scholar
Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecularweight heparin. Ann Intern Med 1990 Oct 15; 113: 571–4 PubMedCAS Google Scholar
Hauch O, Jørgensen LN, Kølle TR, et al. Low molecular weight heparin (Logiparin™) as thromboprophylaxis in elective abdominal surgery: a dose finding study. Acta Chir Scand Suppl 1988; 543: 90–5 PubMedCAS Google Scholar
Green D, Chen D, Chmiel JS, et al. Prevention of thromboembolism in spinal cord injury: role of low molecular weight heparin. Arch Phys Med Rehabil 1994; 75: 290–2 ArticlePubMedCAS Google Scholar
Planès A. An equivalence study of two low-molecularweight heparins in the prevention and treatment of deepvein thrombosis after total hip replacement. Semin Thromb Hemost 2000; 26 Suppl. 1: 57–60 ArticlePubMed Google Scholar
Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005 Apr 11; 165(7): 733–8 ArticlePubMedCAS Google Scholar
Hull RD, Raskob GE, Brant RF, et al. Low-molecularweight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000 Jan 24; 160(2): 229–36 ArticlePubMedCAS Google Scholar
Hull RD, Pineo GF, Brant RF, et al. Self-managed longterm low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007 Jan; 120(1): 72–82 ArticlePubMedCAS Google Scholar
Hull RD, Pineo GF, Brant R, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009 Aug; 122(8): 762–9.e3 ArticlePubMed Google Scholar
Romera A, Cairols MA, Vila-Coll R, et al. A randomised open-label trial comparing long-term sub-cutaneous lowmolecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009 Mar; 37(3): 349–56 ArticlePubMedCAS Google Scholar
Lapidus L, Börretzen J, Fahlén M, et al. Home treatment of deep vein thrombosis: an out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients. Pathophysiol Haemost Thromb 2002 Mar; 32(2): 59–66 ArticlePubMedCAS Google Scholar
Leizorovicz A, on behalf of the IRIS Group. Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency: the IRIS trial [abstract no. 434]. Blood 2008 Nov 16; 112(11): 166 Google Scholar
Beijering RJR, ten Cate H, Stevens P, et al. Randomised long-term comparison of tinzaparin and dalteparin in haemodialysis. Clin Drug Investig 2003; 23(2): 85–97 ArticleCAS Google Scholar
Simpson HKL, Baird J, Allison M, et al. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis. Haemostasis 1996; 26: 90–7 PubMedCAS Google Scholar
Ryan KE, Lane DA, Flynn A, et al. Dose finding study of low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost 1991; 66(3): 277–82 PubMedCAS Google Scholar
Bramham K, Varrier M, Asgari E, et al. Comparison of tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity. Nephron Clin Pract 2008; 110(2): c107–13 ArticlePubMedCAS Google Scholar
Egfjord M, Rosenlund L, Hedegaard B, et al. Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis. Artif Organs 1998; 22(8): 633–7 ArticlePubMedCAS Google Scholar
Lord H, Jean N, Dumont M, et al. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 2002; 22(1): 58–66 ArticlePubMed Google Scholar
Leo Pharma Inc. Product monograph PRinnohep® (tinzaparin sodium injection) anticoagulant/antithrombotic agent [online]. Available from URL: http://www.hc-sc.gc.ca [Accessed 2010 Mar 15]
Bates SM, Ginsberg JS. Clinical practice: treatment of deepvein thrombosis. N Engl J Med 2004 Jul 15; 351(3): 268–77 ArticlePubMedCAS Google Scholar
Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008 Sep; 29(18): 2276–315 ArticlePubMedCAS Google Scholar
Krishnan JA, Segal JB, Streiff MB, et al. Treatment of venous thromboembolism with low-molecular-weight heparin: a synthesis of the evidence published in systematic literature reviews. Respir Med 2004 May; 98(5): 376–86 ArticlePubMedCAS Google Scholar
Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007 Feb 6; 146(3): 211–22 PubMed Google Scholar
Myers J. Selecting an agent for prophylaxis of venous thromboembolism. Am J Health Syst Pharm 2006 Dec 15; 63(24): 2448–50 ArticlePubMed Google Scholar
Messmore HL, Coyne E, Wehrmacher WH, et al. Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review. Curr Pharm Des 2004; 10(9): 1001–10 ArticlePubMedCAS Google Scholar
Wolf H. Low-molecular-weight heparin. Med Clin North Am 1994 May; 78(3): 733–43 PubMedCAS Google Scholar
Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008 Jun; 133 (6 Suppl.): 454S–545S ArticlePubMedCAS Google Scholar
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008 Jun; 133 (6 Suppl.): 381S–453S ArticlePubMedCAS Google Scholar
Patel JP, Hunt BJ. Where do we go now with low molecular weight heparin use in obstetric care? J Thromb Haemost 2008 Sep; 6(9): 1461–7 ArticlePubMedCAS Google Scholar
Lykke JA, Grønlykke T, Langhoff-Roos J. Treatment of deep venous thrombosis in pregnant women. Acta Obstet Gynecol Scand 2008; 87(11): 1248–51 ArticlePubMed Google Scholar
Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008 Jun; 133 (6 Suppl.):844S–86S ArticlePubMedCAS Google Scholar
Spyropoulos AC, Merli G. Management of venous thromboembolism in the elderly. Drugs Aging 2006; 23(8): 651–71 ArticlePubMedCAS Google Scholar